Clinical and immunological features of convalescent pediatric patients infected with the SARS-CoV-2 Omicron variant in Tianjin, China

Jing-Yu Wang; Tian-Ning Li; Chun-Lei Zhou; Jie Zhao; Meng Wang; Yuan Wang; Yan Jiang; He-Nan Dong; Qian-Ru Qi; Hong Mu

doi:10.1016/j.virs.2022.10.009

December 2022

. doi: 10.1016/j.virs.2022.10.009

Citation: Jing-Yu Wang, Tian-Ning Li, Chun-Lei Zhou, Jie Zhao, Meng Wang, Yuan Wang, Yan Jiang, He-Nan Dong, Qian-Ru Qi, Hong Mu. Clinical and immunological features of convalescent pediatric patients infected with the SARS-CoV-2 Omicron variant in Tianjin, China .VIROLOGICA SINICA, 2022, 37(6) : 850-859. http://dx.doi.org/10.1016/j.virs.2022.10.009

中国天津地区感染SARS-CoV-2 Omicron变异株的恢复期儿童患者的临床及免疫学特征

王景雨 ^a ,
李天宁 ^a ,
周春雷 ^a ,
赵洁 ^a ,
王猛 ^a ,
王媛 ^a ,
江雁 ^a ,
董贺楠 ^b ,
戚倩如 ^c ,
穆红 ^a,,

天津市第一中心医院

通讯作者： 穆红, tjmuhong@163.com
收稿日期： 2022-04-24
录用日期： 2022-10-27

摘要

COVID-19在全球范围内以惊人的速度传播，新的变体不断出现。最近，世界卫生组织承认了一种新的变异株“Omicron”，与其他变异株相比，儿童在该变异株引起的COVID-19病例中所占的比例越来越大。然而，Omicron感染后恢复期儿童患者的临床和免疫学特征尚不清楚。在本研究中，我们将儿童患者与成年患者或健康儿童的临床数据进行了比较分析，并探究了SARS-CoV-2疫苗对恢复期儿童患者临床和免疫特征的影响。该研究结果表明，恢复期儿童患者具有与成年患者或健康儿童不同的独特临床和免疫特征。此外，接种SARS-CoV-2疫苗对恢复期患者临床和免疫特征及预防RP有显著影响。我们的研究进一步加深了对Omicron对儿童患者长期健康影响的认识，同时也为Omicron感染儿童的预防和治疗提供了重要参考。
- 新冠肺炎
- , 奥密克戎变异株
- , 临床特征
- , 儿童患者
- , 新冠疫苗

Clinical and immunological features of convalescent pediatric patients infected with the SARS-CoV-2 Omicron variant in Tianjin, China

Jing-Yu Wang ^a ,
Tian-Ning Li ^a ,
Chun-Lei Zhou ^a ,
Jie Zhao ^a ,
Meng Wang ^a ,
Yuan Wang ^a ,
Yan Jiang ^a ,
He-Nan Dong ^b ,
Qian-Ru Qi ^c ,
Hong Mu ^a,,

a Department of Clinical Lab, Tianjin First Central Hospital, Tianjin, 300192, China;
b The First Central Clinical College, Tianjin Medical University, Tianjin, 300192, China;
c Department of Clinical Lab, Tianjin Children's Hospital, Tianjin, 300074, China

Corresponding author: Hong Mu, tjmuhong@163.com
Received Date: 24 April 2022
Accepted Date: 27 October 2022

Abstract

COVID-19 has spread surprisingly fast worldwide, and new variants continue to emerge. Recently, the World Health Organization acknowledged a new mutant strain “Omicron”, with children were accounting for a growing share of COVID-19 cases compared with other mutant strains. However, the clinical and immunological characteristics of convalescent pediatric patients after Omicron infection were lacking. In this study, we comparatively analyzed the clinical data from pediatric patients with adult patients or healthy children and the effects of SARSCoV-2 vaccine on the clinical and immune characteristics in convalescent pediatric patients. Our results indicated that convalescent pediatric patients had unique clinical and immune characteristics different from those of adult patients or healthy children, and SARS-CoV-2 vaccination significantly affected on the clinical and immune characteristics and the prevention of nucleic acid re-detectable positive (RP) in convalescent patients. Our study further deepens the understanding of the impact of Omicron on the long-term health of pediatric patients and provides a valuable reference for the prevention and treatment of children infected with Omicron.
- COVID-19
- , SARS-CoV-2 Omicron variant
- , Clinical characteristics
- , Pediatric patients
- , SARS-CoV-2 vaccine

References
1. An, J., Liao, X., Xiao, T., Qian, S., Yuan, J., Ye, H., Qi, F., Shen, C., Wang, L., Liu, Y., Cheng, X., Li, N., Cai, Q., Wang, F.,, Chen, J., Li, G., Cai, Q., Liu, Y., Wang, Y., Zhang, F., Fu, Y., He, Q., Tan, X., Liu, L., Zhang, Z., 2020. Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test. Ann. Transl. Med. 8, 1084.
2. Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., Li, Z., Zhou, G., Gou, J., Qu, J., Sun, Y., Liu, Y., He, Q., Chen, J.,, Liu, L., Xu, L., 2020. COVID-19: abnormal liver function tests. J. Hepatol. 73, 566-574.
3. CDC COVID-19 Response Team, 2021. SARS-CoV-2 B.1.1.529 (omicron) variant -United States, december 1-8, 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 1731-1734.
4. Chang, T.H., Wu, J.L., Chang, L.Y., 2020. Clinical characteristics and diagnostic challenges of pediatric COVID-19: a systematic review and meta-analysis. J. Formos.Med. Assoc. 119, 982-989.
5. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., Ning, Q., 2020a. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620-2629.
6. Chen, J., Zhang, Z.Z., Chen, Y.K., Long, Q.X., Tian, W.G., Deng, H.J., Hu, J.L., Zhang, X.X., Pu, L., Xiang, J.L., Wang, D.X., Hu, P., Zhou, F.C., Li, Z.J., Xu, H.M., Cai, X.F., Wang, D.Q., Hu, Y., Tang, N., Liu, B.Z., Wu, G.C., Huang, A.L., 2020b. The clinical and immunological features of pediatric COVID-19 patients in China. Genes Dis 7, 535-541.
7. Cloete, J., Kruger, A., Masha, M., du Plessis, N.M., Mawela, D., Tshukudu, M., Manyane, T., Komane, L., Venter, M., Jassat, W., Goga, A., Feucht, U., 2021. Rapid Rise in Paediatric COVID-19 Hospitalisations during the Early Stages of the Omicron Wave, Tshwane District, South Africa. https://doi.org/10.1101/ 2021.12.21.21268108 medRxiv.
8. Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., Tong, S., 2020. Epidemiology of COVID-19 among children in China. Pediatrics 145, e20200702.
9. García, L.F., 2020. Immune response, inflammation, and the clinical spectrum of COVID-19. Front. Immunol. 11, 1441.
10. Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., Du, B., Li, L.J., Zeng, G., Yuen, K.Y., Chen, R.C., Tang, C.L., Wang, T., Chen, P.Y., Xiang, J., Li, S.Y., Wang, J.L., Liang, Z.J., Peng, Y.X., Wei, L., Liu, Y., Hu, Y.H., Peng, P., Wang, J.M., Liu, J.Y., Chen, Z., Li, G., Zheng, Z.J., Qiu, S.Q., Luo, J., Ye, C.J., Zhu, S.Y., Zhong, N.S., 2020. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708-1720.
11. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B., 2020. Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet 395, 497-506.
12. Jamal, Z., Haider, M., Ikram, A., Salman, M., Rana, M.S., Rehman, Z., Haider, S.A., Ammar, M., Nisar, N., Umair, M., 2022. Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan. Front. Public Health 10, 987452.
13. Kannan, S., Shaik Syed Ali, P., Sheeza, A., 2021. Omicron (b.1.1.529) - variant of concern- molecular profile and epidemiology: a mini review. Eur. Rev. Med. Pharmacol. Sci. 25, 8019-8022.
14. Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., Xu, H., 2020. Positive RT-PCR test results in patients recovered from COVID-19. JAMA 323, 1502-1503.
15. Lee, J., Park, S., Kim, J.Y., Lim, S.Y., Chang, E., Bae, S., Jung, J., Kim, M.J., Chong, Y.P., Lee, S.O., Choi, S.H., Kim, Y.S., Lee, N., Shum, D., Kim, S., Jee, Y., Kim, S.H., 2022. No correlation of neutralizing antibody titers against the omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough omicron infections among healthcare workers. J. Infect. S0163-4453(22)00600-4.
16. Li, Q., Shuai, L., Tan, L., Song, L., Ou, C., Song, X., He, J., Gao, M., Hu, X., Liu, Y., Chen, H., Zou, Z., Yu, C., Qin, B., Xu, W., 2021. Clinical characteristics and prediction analysis of the recovered COVID-19 patients with re-detectable positive rna test. Am J Transl Res 13, 14157-14167.
17. Ling, Y., Xu, S.B., Lin, Y.X., Tian, D., Zhu, Z.Q., Dai, F.H., Wu, F., Song, Z.G., Huang, W., Chen, J., Hu, B.J., Wang, S., Mao, E.Q., Zhu, L., Zhang, W.H., Lu, H.Z., 2020.
18. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin. Med. J. 133, 1039-1043.
19. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W.J., Wang, D., Xu, W., Holmes, E.C., Gao, G.F., Wu, G., Chen, W., Shi, W., Tan, W., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565-574.
20. Nardo, A.D., Schneeweiss-Gleixner, M., Bakail, M., Dixon, E.D., Lax, S.F., Trauner, M., 2021. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 41, 20-32.
21. Nikolopoulou, G.B., Maltezou, H.C., 2022. COVID-19 in children: where do we stand? Arch. Med. Res. 53, 1-8.
22. Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., Tian, D.S., 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China. Clin. Infect. Dis. 71, 762-768.
23. Qiu, H., Wu, J., Hong, L., Luo, Y., Song, Q., Chen, D., 2020. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID -19) in zhejiang, China: an observational cohort study. Lancet Infect. Dis. 20, 689-696.
24. Qu, Y.M., Kang, E.M., Cong, H.Y., 2020. Positive result of SARS-CoV-2 in sputum from a cured patient with COVID-19. Trav. Med. Infect. Dis. 34, 101619.
25. Schmidt, F., Weisblum, Y., Rutkowska, M., Poston, D., DaSilva, J., Zhang, F., Bednarski, E., Cho, A., Schaefer-Babajew, D.J., Gaebler, C., Caskey, M., Nussenzweig, M.C., Hatziioannou, T., Bieniasz, P.,D., 2021. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512-516.
26. Skok, K., Stelzl, E., Trauner, M., Kessler, H.H., Lax, S.F., 2021. Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage.
27. Virchows Arch. 478, 343-353.
28. Štefan, M., Dlouhý, P., Bezdíčková, L., 2021. Vaccination against COVID-19. Klinická Mikrobiol. a Infekcní Lékarství 27, 49-60 (In Czech).
29. Tezer, H., Bedir Demirdağ, T., 2020. Novel coronavirus disease (COVID-19) in children. Turk. J. Med. Sci. 50, 592-603.
30. Tian, D., Sun, Y., Xu, H., Ye, Q., 2022. The emergence and epidemic characteristics of the highly mutated sars-cov-2 omicron variant. J. Med. Virol. 94, 2376-2383.
31. World Health Organization, 2020. Laboratory Testing Strategy Recommendations for COVID-19: Interim Guidance. https://www.who.int/publications/i/item/laboratory-testing-strategy-recommendations-for-covid-19-interim-guidance. (Accessed 21 March 2020).
32. World Health Organization, 2021. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www.who.intnewsitem/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern. (Accessed 26 November 2021).
33. Wu, H., Zhu, H., Yuan, C., Yao, C., Luo, W., Shen, X., Wang, J., Shao, J., Xiang, Y., 2020. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in wuhan, China. JAMA Netw. Open 3, e2010895.
34. Xu, L., Liu, J., Lu, M., Yang, D., Zheng, X., 2020. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 40, 998-1004.
35. Zhang, C., Shi, L., Wang, F.S., 2020. Liver injury in COVID -19: management and challenges. Lancet Gastroenterol Hepatol 5, 428-430.
36. Zhang, X., Wu, S., Wu, B., Yang, Q., Chen, A., Li, Y., Zhang, Y., Pan, T., Zhang, H., He, X., 2021. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct. Targeted Ther. 6, 430.
37. Zhang, Y., Han, S., Yao, M., Guo, X., Zhao, L., Sun, W., Wang, S., Pang, B., Zhang, S., Wang, J., Fang, M., Liu, X., Kou, Z., Jiang, X., 2022. Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron variant. J. Infect. S0163-4453(22) 00620-X.
38. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., Chen, H.D., Chen, J., Luo, Y., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R., Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Liu, L.L., Yan, B., Zhan, F.X., Wang, Y.Y., Xiao, G.F., Shi, Z.L., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.
Proportional views
Electronic Supplementary Material

10.1016j.virs.2022.10.009-ESM.docx